Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 1.91 USD 6.11% Market Closed
Market Cap: 159.9m USD

Intrinsic Value

EDIT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one EDIT stock under the Base Case scenario is 1.28 USD. Compared to the current market price of 1.91 USD, Editas Medicine Inc is Overvalued by 33%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

EDIT Intrinsic Value
1.28 USD
Overvaluation 33%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Editas Medicine Inc

Valuation History Unavailable

Historical valuation for EDIT cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about EDIT?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Editas Medicine Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Editas Medicine Inc

Current Assets 224.8m
Cash & Short-Term Investments 221m
Receivables 510k
Other Current Assets 3.4m
Non-Current Assets 38.8m
PP&E 34.6m
Other Non-Current Assets 4.2m
Efficiency

Free Cash Flow Analysis
Editas Medicine Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Editas Medicine Inc

Revenue
35.8m USD
Operating Expenses
-243.1m USD
Operating Income
-207.2m USD
Other Expenses
-44m USD
Net Income
-251.2m USD
Fundamental Scores

EDIT Profitability Score
Profitability Due Diligence

Editas Medicine Inc's profitability score is 10/100. The higher the profitability score, the more profitable the company is.

Positive 3-Years Revenue Growth
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
10/100
Profitability
Score

Editas Medicine Inc's profitability score is 10/100. The higher the profitability score, the more profitable the company is.

EDIT Solvency Score
Solvency Due Diligence

Editas Medicine Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Low D/E
Long-Term Solvency
54/100
Solvency
Score

Editas Medicine Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EDIT Price Targets Summary
Editas Medicine Inc

Wall Street analysts forecast EDIT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EDIT is 3.44 USD with a low forecast of 1.01 USD and a high forecast of 5.25 USD.

Lowest
Price Target
1.01 USD
47% Downside
Average
Price Target
3.44 USD
80% Upside
Highest
Price Target
5.25 USD
175% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Editas Medicine Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for EDIT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

EDIT Insider Trading
Buy and sell transactions by insiders

EDIT News

Other Videos
What is the Intrinsic Value of one EDIT stock?

The intrinsic value of one EDIT stock under the Base Case scenario is 1.28 USD.

Is EDIT stock undervalued or overvalued?

Compared to the current market price of 1.91 USD, Editas Medicine Inc is Overvalued by 33%.

Back to Top